• menu
    Market Place Market Place
    Sourcing support Sourcing Support
    API / FDF
    Excipients
    Services
    Developments
    News
    Market Intel
    #Phispers
    #SpeakPharma
    #LearnMore

    NEWS

    DRUGS & DEVELOPMENTS

    MARKET INTEL by PharmaCompass

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.
    All News #Library
    Others

    FORE Bio to Participate in Upcoming Investor Conferences

    BUSINESSWIRE

    FORE Biotherapeutics Reports Positive Interim FORTE Study Data

    BUSINESSWIRE

    FORE Biotherapeutics at Jefferies Global Healthcare Conference

    BUSINESSWIRE

    FORE Biotherapeutics Raises $38M for Plixorafenib Advancement

    BUSINESSWIRE

    FORE Bio to Present Plixorafenib Abstracts at AACR Meeting

    BUSINESSWIRE

    FORE Biotherapeutics Shares Oncology Pipeline Progress & Goals

    BUSINESSWIRE

    FORE Bio to Present at 43rd J.P. Morgan Healthcare Conference

    BUSINESSWIRE

    FORE Biotherapeutics to Participate in Upcoming Nov Conferences

    BUSINESSWIRE

    FORE Biotherapeutics to Participate in Upcoming Investor Conferences

    BUSINESSWIRE

    FORE Biotherapeutics Names William R. Hinshaw as Chief Executive Officer

    BUSINESSWIRE

    FORE Biotherapeutics to Participate in Upcoming Investor Conferences

    BUSINESSWIRE

    FORE Biotherapeutics to Present at the 2023 RBC Capital Markets Conference

    BUSINESSWIRE

    FORE Biotherapeutics Announces Oral Presentation of Phase 1/2a Plixorafenib Data

    BUSINESSWIRE

    FORE Biotherapeutics to Present Plixorafenib Nonclinical Data

    BUSINESSWIRE

    FORE Biotherapeutics Announces $75M in Series D Financing and CEO Transition

    BUSINESSWIRE

    FORE to Present Promising New Data from Phase 1/2a Trial Evaluating Plixorafenib

    BUSINESSWIRE

    FORE Biotherapeutics Announces 2 Abstracts Accepted for Presentation at the 2023

    BUSINESSWIRE

    Fore Announces First Patient Dosed in Global Phase 2 Trial Evaluating FORE8394

    BUSINESSWIRE

    Fore Biotherapeutics Announces Fast Track Designation Granted by FDA to FORE8394

    BUSINESSWIRE

    Fore Presents Positive Interim Data From Phase 1/2a Trial Evaluating FORE8394

    BUSINESSWIRE

    Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.